Table 4.
Less Common Intralesional Therapies
| Treatment | Number of Studies | Total Number of Patients |
|---|---|---|
| Bleomycin | 6 | 234 |
| MIP vaccine (Mw) | 3 | 114 |
| 5-FU | 3 | 84 |
| Zinc sulfate | 2 | 73 |
| Human serum albumin and lactose | 1 | 64 |
| IFN beta | 1 | 64 |
| IFN alfa-2b | 2 | 56 |
| Mumps, Candida, or trichophyton antigens | 1 | 54 |
| PPD + cryotherapy | 2 | 50 |
| Mumps /trichophyton/candida antigens + IFN alfa-2b | 1 | 41 |
| Alternating PPD and Candida | 1 | 40 |
| BCG-PSN vaccine | 1 | 40 |
| Intralesional Candida with oral isotretinoin | 1 | 36 |
| Vitamin A | 1 | 24 |
| HPV vaccine | 1 | 22 |
| IFN alfa-2b + pulse-dyed laser | 1 | 13 |
| Hydrocortisone acetate | 1 | 6 |
Abbreviations: 5-FU, 5 fluorouracil; BCG-PSN, Bacillus Calmette–Guerin polysaccharide nucleic acid; Candida, Candida antigen; HPV, human papillomavirus; MIP, Mycobacterium indicus pranii; Mw, Mycobacterium; PPD, purified protein derivative; IFN, interferons; RCT, randomized controlled trial.
MIP is formerly known as Mw. All of these therapies are described in less than 10 RCTs.